STORM Therapeutics To Present Promising Phase 1 Sarcoma Data Demonstrating Activity Of First‐In‐Class METTL3 Inhibitor STC‐15 At ASCO 2026

(MENAFN - GlobeNewsWire - Nasdaq) Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression ...